bosentan anhydrous has been researched along with Coronary Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McCulloch, J; Patel, TR | 1 |
| Clozel, M; Fleisch, M; Jones, CR; Kaufmann, U; Lüscher, TF; Meier, B; Noll, G; Schmitt, R; Shaw, S; Wenzel, RR | 1 |
| Barton, M; Glodny, B | 1 |
1 trial(s) available for bosentan anhydrous and Coronary Disease
| Article | Year |
|---|---|
Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease.
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Bosentan; Coronary Disease; Coronary Vessels; Double-Blind Method; Endothelins; Heart Rate; Hemodynamics; Humans; Middle Aged; Sulfonamides | 1998 |
2 other study(ies) available for bosentan anhydrous and Coronary Disease
| Article | Year |
|---|---|
Postischemic hypoperfusion in transient global ischemia: a role for endothelins?
Topics: Animals; Arterial Occlusive Diseases; Bosentan; Cerebrovascular Circulation; Coronary Disease; Endothelins; Hypotension; Ischemic Attack, Transient; Male; Rats; Rats, Sprague-Dawley; Sulfonamides | 1995 |
Endothelin receptor blockade and nitric oxide bioactivity.
Topics: Acetylcholine; Bosentan; Coronary Artery Bypass; Coronary Disease; Endothelin Receptor Antagonists; Endothelium, Vascular; Female; Humans; In Vitro Techniques; Male; Mammary Arteries; Nitric Oxide; Oligopeptides; Peptides, Cyclic; Piperidines; Receptors, Endothelin; Sulfonamides; Vasodilation; Vasodilator Agents | 2001 |